Compare iShares Global Tech ETF (IXN) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs McKesson Corporation — how do they compare? iShares Global Tech ETF trades at $149.76 (market cap $10.03B), while McKesson Corporation trades at $937.78 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 10.8× iShares Global Tech ETF's market cap, and McKesson Corporation pays a 0.4% dividend while iShares Global Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 46 Days and McKesson Corporation for 74 Days on average.
| IXN | MCK | |
|---|---|---|
Market Cap | $10.03B | $108.46B |
Volume | 286,617 | 712,607 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $995.69 |
52-Week Low | $95.76 | $725.17 |
Typical Hold Time | 46 Days | 74 Days |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $152.16, down 0.51% today but near its 52-week high of $151.40, reflecting strong momentum. Technical indicators show a bullish moving average signal but overbought RSI levels. Recent news highlights the ETF's 34% gain and multiple compression, with a high-teens P/E ratio and 28.5% long-term EPS growth rate, emphasizing global tech exposure beyond the U.S.
The outlook remains positive due to AI exposure and global diversification, but risks include portfolio concentration and overbought conditions. Analyst sentiment is bullish, with buy ratings citing valuation appeal, though investors should monitor tech sector volatility and competitive pressures from international firms.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
